Lifetime cardiovascular management of patients with previous Kawasaki disease. by Brogan, Paul et al.
UC San Diego
UC San Diego Previously Published Works
Title
Lifetime cardiovascular management of patients with previous Kawasaki disease.
Permalink
https://escholarship.org/uc/item/65r0d777
Journal
Heart (British Cardiac Society), 106(6)
ISSN
1355-6037
Authors
Brogan, Paul
Burns, Jane C
Cornish, Jacqueline
et al.
Publication Date
2020-03-01
DOI
10.1136/heartjnl-2019-315925
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
  411Brogan P, et al. Heart 2020;106:411–420. doi:10.1136/heartjnl-2019-315925
Review
Lifetime cardiovascular management of patients 
with previous Kawasaki disease
Paul Brogan,1 Jane C Burns,2,3 Jacqueline Cornish,4 vinod Diwakar,5 
Despina eleftheriou,1 John B Gordon,6 Huon Hamilton Gray,7 
Thomas william Johnson,8 Michael Levin,9 iqbal Malik,10 Philip MacCarthy,11 
Rachael McCormack,12 Owen Miller,13 Robert M R Tulloh   ,14,15 Kawasaki Disease 
writing Group, on behalf of the Royal College of Paediatrics and Child Health, and the 
British Cardiovascular Society
Expert consensus statement
To cite: Brogan P, Burns JC, 
Cornish J, et al. Heart 
2020;106:411–420.
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
heartjnl- 2019- 315925).
For numbered affiliations see 
end of article.
Correspondence to
Professor Robert M R Tulloh, 
Department of Congenital Heart 
Disease, Bristol Royal Hospital 
for Children, Bristol BS2 8BJ, 
UK;  robert. tulloh@ bristol. ac. uk
Received 4 September 2019
Revised 5 November 2019
Accepted 7 November 2019
Published Online First 
16 December 2019
 heart. bmj. com
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
AbsTrACT
Kawasaki disease (KD) is an inflammatory disorder of 
young children, associated with vasculitis of the coronary 
arteries with subsequent aneurysm formation in up to 
one- third of untreated patients. Those who develop 
aneurysms are at life- long risk of coronary thrombosis or 
the development of stenotic lesions, which may lead to 
myocardial ischaemia, infarction or death. The incidence 
of KD is increasing worldwide, and in more economically 
developed countries, KD is now the most common 
cause of acquired heart disease in children. However, 
many clinicians in the UK are unaware of the disorder 
and its long- term cardiac complications, potentially 
leading to late diagnosis, delayed treatment and poorer 
outcomes. increasing numbers of patients who suffered 
KD in childhood are transitioning to the care of adult 
services where there is significantly less awareness and 
experience of the condition than in paediatric services. 
The aim of this document is to provide guidance on the 
long- term management of patients who have vascular 
complications of KD and guidance on the emergency 
management of acute coronary complications. Guidance 
on the management of acute KD is published elsewhere.
bACKground
Kawasaki disease (KD) was first described in Japan 
in 1967, predominantly affects young children and 
has potential life- long consequences.1–4 Its incidence 
in children under 5 years ranges from 322/100 000 
in Japan and South East Asian countries, to 4.5–
25/100 000 in Europe and USA3–5 and the disease 
has become increasingly common in the UK.6 7 Its 
cause is unknown, but epidemiological observations 
suggest an environmental agent causing an inflamma-
tory process in genetically predisposed individuals.8 
Although the acute febrile and exanthematous illness 
resolves spontaneously, 30% of untreated patients 
develop coronary artery aneurysms (CAA).9
Treatment of the acute illness with intravenous 
immunoglobulin (IVIG) reduces the risk of CAA,10 
and is now the standard recommended treatment.2 11 
The 10%–15% of patients who are unresponsive to 
IVIG may be treated with corticosteroids, inflix-
imab or other immunosuppressive agents2 and are at 
increased risk of CAA, as are those in whom treatment 
is delayed.12 13 Following an acute episode of KD, 
British Paediatric Surveillance Unit data suggest that 
19% of children overall and 39% of those aged under 
1 year, still develop coronary involvement6 despite 
IVIG, partly related to delayed diagnosis and treat-
ment. Such children are at long- term risk of coronary 
thrombosis, acute coronary syndrome and progres-
sive coronary stenoses.13–15 Comparably high rates of 
CAA have also recently been reported from Sweden, 
Russia, Germany and North America.16–18
Although paediatricians are familiar with acute KD, 
there is less awareness of its long- term consequences 
and management of any subsequent acute coronary 
syndrome, in both paediatric and adult services. 
To help raise awareness a guidance document was 
produced by NHS England London Cardiac Stra-
tegic Clinical Network in 201519 and a national NHS 
Patient Safety Alert in 2016.20
Methodology
A writing group was convened to obtain consensus 
from experts in the UK and USA, concerning the 
long- term management of patients who had coronary 
artery complications from KD. A literature search 
was performed and data reviewed by convened 
experts resulting in wide ranging consensus across 
the UK and USA. Clinical and other specialists were 
in the areas of Paediatric Cardiology (RMT/OM/
JCB), Adult Cardiology (TWJ/VD/HG/JG/PM/IM), 
Paediatric Rheumatology (PG/DE), Paediatric infec-
tious disease (ML), NHS England (JC/HG), Societi 
patient charity (RM). Face to face meetings were 
held to derive consensus and external expert advice 
sought from individuals including emergency medi-
cine, ambulance services, patient charities and phar-
macy. In addition, endorsement and/or support was 
obtained from the organisations of the Royal College 
of Paediatrics and Child Health, Royal College of 
Physicians, British Cardiovascular society and the 
Royal College of Emergency Medicine.
CArdiovAsCuLAr ConsEquEnCEs of 
KAwAsAKi disEAsE
All cardiac tissues are involved in the acute inflam-
matory phase of the disease.9 Vasculitis causes 
destruction of the normal arterial architecture and 
is followed by aneurysmal dilatation, particularly 
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Table 1 Classification of coronary artery dilation or aneurysms (after AHA guidance with modification)11
Classification 
of risk level description of coronary arteries follow- up interval
imaging required to assess for inducible 
ischaemia (stress echo or stress Mri) PsP
regional specialist 
Kawasaki disease clinic
1 No involvement at any time point
(Z score<2)
2 weeks
6 weeks
6 months
12 months
Discharge if normal at 
12 months.
None No No—annual cardiac and 
general health review with 
GP recommended*
2 Dilation only
(2<Z score≤2.5): resolves within 1 year
2 weeks
6 weeks
6 months
12 months
Discharge if normal at 
12 months
None No No—annual cardiac and 
general health review with 
GP recommended*
3 Small aneurysm (2.5≤Z score<5):
(a) current or persistent,
(b) decreased to normal or Z score <2.5
2 weeks
6 weeks
6 months
12 months
Annual review
Coronary angiography (preferably CT) at 12 
months as baseline.
Consider stress imaging for inducible myocardial 
ischaemia every 2 years.
Imaging (echo) for coronary surveillance annually
Yes Yes
4 Medium aneurysm (5≤Z score<10):
(a) persistent aneurysm,
(b) decreased to normal or Z score<2.5
2 weeks
6 weeks
6 months
12 months
Annual review
Coronary angiography (preferably CT) at 12 
months as baseline.
Consider stress imaging for inducible myocardial 
ischaemia annually. Imaging (echo, CT† or MRI) 
for coronary thrombus surveillance annually.
Yes Yes
5 Giant aneurysm (Z score≥10 or ≥8 mm):
(a) persistent giant aneurysm,
(b) persistent aneurysm (but regressed to 
medium or small aneurysms),
(c) regressed to normal dimensions
2 weeks
6 weeks
3 months
6 months
9 months
12 months
Then every 6 months
Coronary angiography (preferably CT) at 6–12 
months as baseline.
Consider stress imaging for inducible myocardial 
ischaemia annually.
Imaging (echo, CT† or MRI) for coronary 
thrombus surveillance 6 monthly.
Yes Yes
*GP review should include clinical examination, blood pressure measurement, general health discussion and advice on avoidance of cardiovascular risk factors and lifestyle 
choices—including maintaining a healthy weight, reducing risk of diabetes, avoiding smoking and taking regular exercise. This provides the opportunity to discuss any parent or 
patient questions and concerns.
†CT should not be used repeatedly if possible. Use MRI or ultrasound where possible, to reduce radiation exposure.
ADP, Adenine di- Phosphate; AHA, American Heart Association; FBC, Full blood count; GP, General Practioner; PSP, person- specific protocol.
affecting the proximal coronary arteries.21 22 Pathological studies 
in patients with previous KD reveal widespread changes23 
including inflammatory cell infiltration of the arterial wall, 
disruption of the intima and media, intimal myofibroblastic 
proliferation and replacement of myocytes with fibroblasts and 
connective tissue. Fibrotic changes occur in the myocardium even 
in regions not closely related to aneurysms, probably reflecting 
widespread cardiac inflammation. Arterial remodelling occurs 
and may progress over months to several years with the develop-
ment of coronary stenoses, particularly at the junction between 
the aneurysm and normal artery.23 Calcification is common in 
the aneurysmal arterial wall. Aneurysms of non- coronary arteries 
(axillary, ilio- femoral, renal and popliteal arteries for example 
and rarely in visceral and cerebral arteries) may also occur and 
should be considered and investigated, particularly when coro-
nary involvement is extensive.
Serial echocardiographic studies in acute KD show that CA dila-
tion may be visible early in the illness, but maximal development 
is usually in the second and third week of the acute illness.2 Those 
with persistent CA aneurysm, defined as a Z score≥2.5 after 6 
weeks (Z score=the internal dimension of the coronary artery 
expressed as the number of SD units normalised for body surface 
area) are considered to have suffered long- term arterial damage.11
The risk of thrombotic and stenotic complications is related to 
aneurysm size.24 Large or giant aneurysms (≥8 mm in diameter 
or Z score ≥10) are the least likely to undergo resolution, and 
within 30 years after the initial illness are associated with up to a 
50% risk of thrombotic coronary occlusion, progressive stenoses 
requiring revascularisation or acute coronary syndrome.25 Even 
though the risk of coronary events is lower in those with smaller 
aneurysms longer- term follow- up is still needed. Heart failure 
and serious arrhythmias may also occur later in life.11
AssEssMEnT of CArdiovAsCuLAr risK
As most episodes of acute KD occur in young children, assessment 
for coronary artery involvement is by serial transthoracic echocar-
diography, at diagnosis, 2 weeks and 6 weeks following onset of 
the disease, as a minimum. If abnormal, more frequent echocardi-
ography will be required (up to twice weekly) to identify rapidly 
progressive coronary involvement and/or coronary thromboses. 
Echocardiography should be undertaken by someone appropri-
ately trained and designated as such by the congenital cardiac 
network. Echocardiographic imaging is less definitive in older chil-
dren or adults, for whom CT angiography or MRI may be needed.
On the basis of echocardiography, patients are classified into 
defined risk groups according to the 2017 American Heart Associ-
ation classification,11 each requiring different follow- up (table 1). 
It is recognised that echocardiography of coronary arteries can be 
demanding particularly in very young children. However, the most 
common locations of aneurysms are at the bifurcation of the left 
main coronary artery and in the proximal right coronary artery. 
These areas should be clearly imaged (as an absolute minimum). If 
technical issues limit the examination and it is not possible to obtain 
adequate views of the coronary arteries or calculate Z scores, the 
child should be referred for a repeat examination under sedation, 
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performed by an expert echocardiographer. It should also be noted 
that the measurement of infant length must be carefully executed 
as the Z score calculation is extremely sensitive to variation in body 
surface area that incorporates both height and weight. Aneurysms 
of peripheral arteries may occur in patients with severe coronary 
involvement, so imaging of other vascular territories will also be 
required in these cases.
dEfining PATiEnT grouPs
Acute KD in children results in varying levels of future risk 
following recovery from the acute phase. This guidance has 
been prepared focussing on patients of risk level 3 and above 
(see table 1) who require lifetime specialist management within 
cardiology services. Patients who have had KD but are at risk 
levels 1 or 2 should have follow- up through their General Prac-
titioner. See also notes in table 1.
Patients who have had KD with subsequent coronary or other 
arterial involvement require continued input of a clinician with 
expertise in KD, complementing routine postintervention care and 
taking account of guidance given in table 1. KD presents lifelong 
risks for patients irrespective of intervention on localised aneu-
rysms. Given the low prevalence of children with CAA following 
KD, specific studies in this population are difficult, and posology 
is generally based on adult cardiology principles and some mainly 
retrospective studies of these drugs used in children. The drugs and 
doses proposed are clinically reasonable suggestions for consider-
ation by clinicians, based on available literature evidence, and in 
the absence of trial data (noting that some trial data may become 
available in future for direct oral anticoagulants (DOACs) in KD). 
Many of the indications are not licensed in the paediatric popula-
tion, but it is acknowledged that are no licensed alternatives and 
children with CAA are at risk of cardiovascular events. Throm-
bolysis of a coronary event in a child is rare but medically critical 
and it is preferable to have an indication of agents that might be 
considered in this situation, acknowledging that it is clear there is a 
lack of evidence surrounding paediatric use.
Long-TErM MAnAgEMEnT
The major long- term risks for patients with CAA are thrombosis 
within the aneurysm or coronary stenosis, either of which can 
result in myocardial ischaemia.11 The risk of aneurysm throm-
bosis is greatest in the first 2 years after the acute episode of 
KD but persists life- long.26 Long- term management is based 
on prevention of thrombosis, early detection of thrombosis or 
stenosis when they occur, general measures to lower cardio-
vascular risk (such as lipid lowering, control of hypertension, 
smoking cessation) and support for patients and their families 
to pursue a healthy lifestyle. Evidence levels vary considerably, 
and it is explicit that there is the need for clinicians to consider 
evidence levels and individual benefit risk, including discussions 
with patients and/or their guardian.
Antithrombotic therapy
Antiplatelet agents
All patients with KD receive aspirin during the acute illness, 
along with gastric protection if needed. Those who have CAA 
(persisting after 6 weeks) should remain on long- term aspirin 
(see online supplementary drug appendix for all doses), including 
those in whom there is later remodelling of the CAA. It needs 
to be remembered that the switch from high- dose to low- dose 
aspirin is to minimise the risk of thrombosis in situ, following 
evidence from those who have had myocardial infarction.27 
Those with giant CAA should remain on low dose aspirin (or 
clopidogrel) and have an anticoagulant added. Other antiplatelet 
medications (such as ticagrelor) have been used but on the basis 
of evidence derived from non- KD populations. The alternative 
of an antagonist of ADP mediated activation of platelet aggre-
gation such as clopidogrel may be considered in individuals 
where the use of aspirin is problematic, for example, in patients 
requiring non- steroidal anti- inflammatory drugs (NSAIDs) for 
other comorbidities such as arthritis, since NSAIDs interfere 
with the antiplatelet effect of aspirin.11 In addition, clopidogrel 
(or other thienopyridine) may be added to aspirin therapy for 
those with large but not giant aneurysms, based on the inference 
from adult trials that this would be a more effective antiplatelet 
strategy.11
Anticoagulants
There are no randomised controlled trials of anticoagulation 
therapy in KD but there is a lower rate of CAA thrombosis and 
better outcome for patients with giant aneurysms maintained on 
long- term warfarin.11 Although warfarin is the most widely used 
anticoagulant, it is difficult to use in very young children, and 
a subcutaneous low molecular weight heparin (such as Enoxa-
parin) is preferable converting to warfarin in older children.28 29 
Although clinical trials are underway, direct oral antithrombins 
(or DOACs) are increasingly used in adults, under expert super-
vision, when warfarin is felt to be inappropriate or insufficiently 
effective (for instance, due to failure to achieve an INR consis-
tently in the therapeutic range or thrombus formation while on 
warfarin). These may become a future alternative to heparin or 
warfarin in children and young adults, but trials regarding safety 
and efficacy are currently lacking and therefore this cannot be 
routinely recommended at the time of writing.
Data from Japan show that the risk of thrombosis in children 
with giant CAA is greatest in the first 2 years after disease onset, 
but persists throughout life26 and a US study showed that aneu-
rysm size was the strongest predictor of major cardiac events.18 
Combined anticoagulation and antiplatelet therapy are therefore 
recommended for all patients with KD with a coronary artery Z 
score ≥10.11
other drug therapies
Beta-blockers
Not routinely prescribed but may be appropriate for some cases 
of CAA when associated with myocardial ischaemia or if anti-
arrhythmic therapy is indicated. The current advice is for beta 
blockers to be used lifelong in patients with prior infarction and 
depressed (<40%) ejection fraction.
Statins
Although the pathology of KD differs from that of atheroscle-
rotic heart disease, and despite a lack of definitive evidence, 
statins should be considered for patients with persisting CAA 
due to the potential benefit of their anti- inflammatory effect.30
For all the drug therapies, physicians should consult the SmPC, 
consider BNFc posology where available and also check for any 
relevant Direct Healthcare Professional Communications.
Avoidance of cardiovascular risk factors
Patients who have ever had CAA should be counselled to lower 
their cardiovascular risk from an early age, by measures such as 
eating a diet low in animal fat, taking regular and appropriate 
exercise, maintenance of ideal weight (reducing the risk of 
diabetes), avoidance of smoking and monitoring for hyperten-
sion and hyperlipidaemia.
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Table 2 Follow- up assessments
Assessment Each visit Additionally at transition
Clinical History
Examination
Medication review
ECG 12 lead
Imaging
(see also table 1)
Echocardiography CT calcium scoring and 
angiography with ischaemia 
testing (stress MRI, stress echo, 
CTFFR) if indicated prior to 
transition to adult services
Blood tests Lipid profile every 5 years 
HbA1c
Psychological Family and patient dialogue During transition process 
from 13 to 18 years—patient 
focused dialogue
Advice Smoking
Exercise
Diet
Family planning
PSP review
ADP, Adenine di- Phosphate; AHA, American Heart Association; CTFFR, CT fractional 
flow reserve; PSP, person- specific protocol.
Exercise
After the acute illness, patients with previous KD should be 
encouraged to undertake regular aerobic exercise which is 
tailored to their disease severity. Competitive sports may need 
to be restricted in those with giant aneurysms, and body contact 
sports should be avoided in patients on anticoagulants.
Psychological support
Children may suffer psychological stress adjusting to teenage 
and young adult life with the constant threat of an acute coro-
nary ischaemic event. Care teams have to balance providing 
honest advice on the risks, and the need for urgent action in 
the event of changing symptoms, with the value of reassurance 
and helping families to live as normal a life as possible. Multi-
disciplinary team involvement, including access to counselling 
and psychological support should be part of the specialist service 
provided to patients with KD.
regular clinical assessment and investigations
Table 1 suggests the frequency of cardiovascular follow- up and 
recommends imaging/stress testing, by level of patient risk. 
Patients with small or remodelled aneurysms may be seen less 
frequently, but those with giant aneurysms need regular imaging 
and assessment to detect developing thrombi within aneurysms, 
particularly in the early years after the acute KD illness, when 
the risk of thrombosis is greatest. Table 2 suggests additional 
tests to be undertaken during a visit, and in the transition period 
from paediatric to adult care, before the decision is made on 
the appropriate long- term follow- up regime. Each assessment 
should focus on evaluating the size of persisting aneurysms, the 
detection of thrombi within aneurysms and whether there is 
evidence of impaired myocardial perfusion suggesting the devel-
opment of coronary stenoses.
imaging considerations
Patients with CAA require repeated assessment throughout life 
and imaging should minimise cumulative radiation exposure, 
using modalities such as echocardiography and MRI. While 
modern multidetector CT can achieve high- resolution coronary 
imaging at much lower radiation doses than in the past, CT (or 
even invasive) coronary angiography should be undertaken only 
when other modalities cannot be used to define stenotic lesions 
or plan interventions. Cardiac MRI has no known risk unless 
gadolinium enhancement is used31 and in addition to providing 
detailed information on aneurysm size and presence of thrombi, 
it can detect small myocardial scars and fibrosis that cannot be 
detected by other modalities.32 Adenosine or exercise stress MRI 
should be used in older children and adults for the investigation 
of myocardial ischaemia. In addition, there may be a role for 
positron emission tomography or nuclear stress imaging in order 
to determine the haemodynamic and perfusion defects in KD, but 
large trials have not yet been performed (only isolated studies), 
so the role of these techniques is not fully established.32–34
If CT angiography at transition demonstrates evidence of coro-
nary artery stenosis or if there is admission with chest pain, then 
ischaemia testing (Stress MRI, Stress echo, CT fractional flow 
reserve) could be considered to determine if there is evidence 
of functional tissue hypoperfusion.35 If this is abnormal, then 
progression to stress imaging with MRI or echocardiography 
should be undertaken. In addition, MRI/MRA should be used 
to screen for non- cardiac aneurysms in cases of severe disease.11
Person-specific protocol
All patients with a history of KD at risk level 3 and above (see 
table 1) require a person- specific protocol (PSP). The PSP (see 
online supplementary file 2) is a guidance document held by the 
patient, parents and school (if a child) the Congenital Cardiac 
Surgical Centre (children)—or Heart Attack Centre (adults) and 
their emergency medical services (including Ambulance Services) 
so they have prior knowledge of the patients’ KD history and can 
act quickly in the event of a suspected cardiac emergency. The 
PSP includes the patient’s KD history and highlights the specific 
instructions to the Ambulance Service regarding the specialist 
centre to which the patient should be transported, where the 
necessary age- appropriate expertise, facilities and imaging are 
available without delay. A suggested template for the KD PSP is 
given as an online supplementary file 2. It is recommended that 
the patient should hold a copy of their most recent ECG and 
their coronary imaging (either digitally or as printed copy), to 
facilitate decision making in the emergency situation.
The PSP should be agreed with the patient (if adult) or carers 
(if child) and should include direct phone contact numbers 
(24 hours) for the specialist KD service, and clear instructions 
regarding who to contact for advice out of hours. It should be 
agreed by the local hospital and ambulance services and should 
be provided to the patient and, as relevant, the patient’s school/
university and/carers parents.
Engagement with primary care
Good communication between the specialist cardiac centre and 
the patient’s Primary Care team is essential. All health, care 
and school services should be aware of plans for the emergency 
management of complications, as documented in the PSP.
TrAnsiTion froM PAEdiATriC To AduLT sErviCEs
All patients with a history of KD and who are in risk level 3 
and above (table 1) require planned transition to adult cardiac 
follow- up at age 16–18 years. The timing of such transi-
tion should reflect the developmental needs of the individual 
concerned. During transition, joint paediatric and adult clinical 
supervision is recommended, until such time as safe transfer of 
care can occur. Transition should be to a specialist KD clinic, 
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figure 1 Kawasaki disease emergency management of suspected myocardial ischaemia in children with previous Kawasaki disease and possible 
coronary artery aneurysms. CAA, coronary artery aneurysms; nSTEMI, non- STEMI; PSP, person- specific protocol; STEMI, ST- elevation myocardial 
infarction.
led by staff with a specific interest in KD, with access to inter-
ventional cardiology, assessment of anticoagulation and 24 hours 
availability of cardiac CT or MRI.
Many children with CAA during the acute illness or persisting 
during early follow- up may have undergone resolution of their 
CAA at the time of transition or their cardiac status may be 
unknown. A rational approach to transition includes making a 
cardiovascular assessment (table 1) together with specific testing 
to detect subclinical ischaemia, valve dysfunction and myocar-
dial fibrosis. Because arterial calcification is a feature of KD 
vascular lesions, the CT calcium score is particularly useful for 
risk stratification of young adults (table 2).36
Myocardial ischaemia may develop in patients with CAA at 
any age, either due to thrombosis within the aneurysm or slow 
development of a coronary stenosis during vascular remodel-
ling. As clinical features cannot reliably determine the under-
lying aetiology, urgent imaging should be undertaken to rule out 
coronary thrombosis in all patients with new onset suspected 
myocardial ischaemia (10) (figures 1 and 2). It is important to 
stress that:
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figure 2 Kawasaki disease emergency management of suspected myocardial ischaemia in adults with previous Kawasaki disease and possible 
coronary artery aneurysms. nSTEMI, non- STEMI; STEMI, ST- elevation myocardial infarction.
1. The classical presentation of myocardial ischaemia in adults 
(chest pain, arm or jaw pain, decreased exercise tolerance, 
breathlessness) may be absent in young children, whose 
symptoms may be non- specific, including poorly localised 
pain, unexplained crying, restlessness, unusual pallor or 
sweating.
2. Children and young adults with stenotic CAA may have well- 
developed collaterals, a greater tolerance for ischaemia and 
may present with atypical symptoms even when extensive 
thrombus is present in the CAA.11
3. In all patients with a previous history of KD CAA, an initial 
ECG and troponin may be unremarkable, even with signifi-
cant myocardial ischaemia.
4. Thrombosis within aneurysms can occur in children and 
adults even when taking anticoagulant and antiplatelet 
agents.
For these reasons, a high index of suspicion is needed in all 
patients with persisting or resolved aneurysms whenever new 
symptoms occur that could represent myocardial ischaemia, 
as potentially life- threatening coronary thrombosis may be the 
cause. Rapid access to urgent expert assessment and imaging is 
needed.
An unusual feature of children with persistent significant 
coronary involvement as a consequence of KD is that they can 
develop significant coronary collaterals over time, such that even 
complete thrombotic occlusion of a coronary artery may not 
result in myocardial ischaemia. Coronary thrombosis per se is 
therefore not necessarily a call to action if there is no myocardial 
territory at risk but always requires rapid review of antithrom-
botic strategy and of the overall management plan. The presence 
of myocardial ischaemia is the most important factor that should 
prompt consideration of coronary intervention.
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Existing care pathways—gaps in paediatric provision
In the UK, adults with suspected acute coronary syndrome 
(ST- elevation myocardial infarction (STEMI) or high- risk 
non- ST elevation myocardial infarction (nSTEMI)) are usually 
taken by the Ambulance Service to a designated Heart Attack 
Centre. Patients presenting to general hospitals undergo emer-
gency triage and are usually then transported to a Heart Attack 
Centre if appropriate. There is no similar arrangement for coor-
dinated management of suspected acute coronary syndromes in 
children. Paediatric services are largely unfamiliar with the detec-
tion and management of myocardial ischaemia due to its rarity 
in children, and many hospital emergency departments for chil-
dren have no on- site paediatric cardiology. Children’s specialist 
cardiac centres are often located away from accident and emer-
gency services or adult interventional cardiology centres.
Addressing gaps
It is therefore essential that, together with general raised aware-
ness of the risk of acute coronary syndrome in people who have 
had a past episode of acute KD, a PSP and local pathway are 
in place for every patient with persistent or remodelled CAA 
so that they can reach the required cardiac expertise rapidly in 
the event of a suspected acute coronary syndrome. These should 
form and inform part of the PSP (see above).
Myocardial ischaemia—presentation to primary or secondary 
care
It is inevitable that some patients, both adults and children, 
will present to a primary or secondary care service where the 
required cardiac expertise is not available. We summarise below 
the potential complications and actions required to ensure 
patients reach appropriate care rapidly.
 ► If the patient does not have a PSP or the deterioration occurs 
at work or school, the patient is likely to be transported by 
ambulance services to the nearest Heart Attack Centre (adult 
patient) if paramedics diagnose STEMI or high risk nSTEMI 
or the nearest children’s accident and emergency centre, 
where the required cardiac expertise may not be available.
 ► Patients with new onset chest pain, exercise induced chest 
pain or (particularly in young children) unusual pallor, 
restlessness, breathlessness, poorly localised pain or unex-
plained crying or collapse should be transported urgently 
to the designated Heart Attack Centre (adults) or nearest 
paediatric cardiac surgical centre or as specified on their PSP.
 ► Unless presentation is clearly due to a non- cardiac condi-
tion (such as acute gastroenteritis, bacterial infection, acute 
abdomen, epilepsy or trauma) patients with known CAA, 
whether persistent or remodelled, should always be evalu-
ated at a Heart Attack Centre (adults) or paediatric cardiac 
surgical centre, as specified on their PSP.
 Acute investigations—paediatric
A pre- existing paediatric KD acute coronary syndrome pathway 
should be in place at the designated centre and the child coman-
aged by the paediatric cardiology team and coronary intervention 
service. Urgent assessment should include clinical examination, 
an ECG, serial high sensitivity troponins and an echocardio-
gram, with awareness and acknowledgement of their PSP, and an 
understanding that absence of ECG changes or rise in troponin 
does not exclude a KD- related cardiac event. If ST elevation is 
present on the ECG, urgent contact with the appropriate inter-
ventional cardiologist should be made, with likely triage direct 
to the cardiac catheter laboratory (see below). If obvious STEMI 
is not present, but acute myocardial ischaemia is suspected, 
imaging by CT angiography or cardiac MRI should be under-
taken to establish whether thrombus formation within a CAA 
has occurred or if coronary stenosis is the cause of symptoms, as 
the therapeutic options differ. Those with thrombus present in 
the coronary aneurysm, but without complete vessel occlusion, 
should be considered for intravenous thrombolysis and inten-
sification of antithrombotic measures. Successful thrombolysis 
can be achieved in over 50% of patients with aneurysms using 
repeated daily infusion of tissue plasminogen activator (tPA) 
(alteplase).37 38 If thrombosis has occurred despite anticoagula-
tion with warfarin, intensification of antithrombotic treatment 
by transfer to unfractionated heparin, switching to a DOAC and 
addition of other antiplatelet agents should be considered in 
adults and might be a possibility in children and young adults if 
their safety and efficacy is confirmed in the future.
 Emergency management of paediatric acute coronary syndrome
Experience from the management of acute coronary syndrome 
in adults has demonstrated the importance of time to coro-
nary reperfusion. Broadly, the longer the time to restoration of 
normal coronary blood flow, the greater the extent of myocar-
dial damage and the worse are outcomes. Most paediatric 
cardiologists have little experience in managing acute myocar-
dial ischaemia, so close collaboration with adult interventional 
cardiology services is essential. With the advent of smaller guide 
catheters and devices, patients with coronary artery internal 
dimensions of at least 1.5 mm are suitable candidates for percu-
taneous coronary intervention (PCI) in the setting of STEMI. 
Technical considerations and the size of the child will determine 
which patients are candidates for PCI or when thrombolysis is 
the preferred initial treatment. A carefully mapped pathway, set 
out and agreed in advance of any emergency event and taking 
account of local context, should be made and documented within 
the PSP in order to ensure a timely and smoothly orchestrated 
response by the paediatric cardiology and supporting adult inter-
ventional cardiology teams.
 Paediatric protocol
Although clear guidelines for adult STEMI have been issued, 
guidance for the paediatric population is limited; box 1 suggests 
a protocol for STEMI or other coronary ischaemic events in 
children
interventional cardiology—all ages
Management of suspected myocardial ischaemia in patients with 
KD aneurysms differs from standard management of adult chest 
pain because of the high risk of large thrombi within coronary 
aneurysms, and the different anatomy of the artery damaged 
by inflammation, calcification and fibrosis as a consequence of 
KD. The procedural aim in the emergency setting should be to 
restore flow as quickly as possible. In the presence of acute occlu-
sion with a large thrombus burden, angioplasty without stenting 
may be the preferred option. Routine thrombus aspiration is 
not supported but may be required to achieve recanalisation, 
acknowledging the associated risk of thromboembolisation.39 
Intravascular ultrasound (IVUS) is essential to assess true vessel 
size and guide management. If the thrombus is not occlusive, 
medical therapy with aspirin, clopidogrel, tPA and IIb/IIIa 
platelet inhibitor should be considered. Other oral antiplatelets 
(such as ticagrelor) have been used but on the basis of evidence 
derived from non- KD populations.40
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box 1 suggested protocol for sT- elevation myocardial 
infarction or other coronary ischaemic events in children
 ► As most children with known coronary artery aneurysms will 
already be on aspirin, additional oral aspirin should only be 
administered if there is uncertainty about compliance or the 
child is not already on aspirin.
 ► If there is ST elevation on the initial ECG, cardiovascular 
collapse or clinical suspicion of myocardial ischaemia and 
expected transport time to a congenital cardiac surgical 
centre with colocated interventional cardiology or Heart 
Attack Centre is more than 90 min, then tissue plasminogen 
activator (tPA) should be administered prior to transport. For 
tPA to be effective, fibrinogen must be >1500 mg/L. If low, 
then intravenous fresh frozen plasma (10–20 mL/kg) should 
be given and a further check performed. While giving tPA, 
unfractionated heparin (UFH) should be commenced through 
a separate line.
 ► If there is ST depression on the ECG, UFH should be started. 
There should be an initial intravenous bolus of 75 units/kg, 
with maintenance of 20 units/kg/hour for target activated 
clotting time 200–250 or an activated partial thromboplastin 
time ratio in the range 1.5–2.5. If there is chest pain, 
sublingual or intravenous glyceryl trinitrate should be started.
 ► Patients too ill to transfer, or in whom delay in transfer to a 
paediatric cardiac surgical centre is likely, should be discussed 
with an interventional cardiologist and thrombolysis 
considered prior to transfer.47
Patients with angina due to stenotic lesions (ie, thrombus 
within the aneurysm is not the cause of ischaemic symptoms) 
may require PCIs. However, a number of issues specific to 
KD pathology need to be considered before any procedure is 
undertaken. The intense luminal myofibroblastic prolifera-
tion and calcification in KD can pose particular challenges to 
interventionists; debulking or modification of calcification with 
rotational atherectomy or cutting balloon technology may be 
required. Due to the severity of vessel wall thickening and asso-
ciated calcification, high balloon inflation pressures may lead to 
neo- aneurysm formation. Moreover, the frequency of a heavy 
thrombus load and the large calibre of the aneurysms themselves 
present additional challenges for coronary stent deployment.
There is limited experience with the use of covered or drug- 
eluting stents in this patient population.41 Intravascular imaging, 
either by IVUS or optical coherence tomography, plays an 
important role in guiding treatment, as inadequate appreciation 
of the diameter of vessels due to thrombus may lead to under-
sizing and/or inappropriate stent placement.14 15 23 42 43
Clopidogrel should be given orally, in addition to aspirin, 
prior to intervention. For additional or postprocedure therapy, 
consider:
 ► Abciximab (currently in short supply): or
 ► Eptifibatide (Integrilin).
 ► Aspirin continued at low dose along with Clopidogrel.
 ► For patients at increased risk of thrombosis (such as those 
with large or giant aneurysms and recent coronary throm-
bosis) ‘triple therapy’ with aspirin, a second antiplatelet 
agent and anticoagulation with warfarin, low molecular 
weight heparin or a direct oral anticoagulant (DOAC) 
should be considered. Trials of DOACs for this clinical indi-
cation are underway; in adults, many already prefer a DOAC 
to warfarin.
 ► Atorvastatin for possible additional anti- inflammatory effect.
 ► In order to reduce the risk of postprocedural heart failure 
and arrhythmia, then beta blockade and ACE inhibitor 
within 24 hours of procedure.
Cardiac surgery
Revascularisation is likely to fail when flow through a partially 
occluded aneurysm competes with graft flow and so bypass 
grafting should not be considered unless flow through the aneu-
rysm is critically reduced. When surgery has been undertaken in 
this patient population both saphenous vein and arterial grafts 
have been used44 but arterial grafts have a much higher rate of 
graft patency over time compared with venous conduits.45 46 
A saphenous graft might supply adequate flow acutely, but the 
conduit may degenerate while the patient is young.
‘Excluding’ an aneurysm (by surgically occluding the native 
coronary artery) at the time of bypass grafting has been under-
taken in some past cases in an attempt to reduce the potential for 
bypass graft occlusion due to competitive flow. This approach 
is not recommended as it has significant associated risks; if the 
aneurysm is excluded, an immature internal mammary LIMA 
graft may not supply adequate blood flow to the left ventric-
ular anterior wall at the time of surgery, resulting in continuing 
ischaemia.
Elective coronary interventions should be planned after 
careful discussion with a broad multidisciplinary team. Cardiac 
transplantation has been successfully performed for the patient 
with rare KD with end- stage cardiomyopathy and inoperable 
multivessel coronary artery disease.
non-CArdiAC CoMPLiCATions
Thrombosis within extracardiac aneurysms
Patients with aneurysms of extracardiac arteries (most 
commonly axillary and iliac/femoral) are at risk of luminal 
thrombosis. This may present with features of peripheral 
ischaemia such as claudication, pallor, pain, loss of pulses 
or discolouration of peripheral limbs or digits. Any acute 
symptoms compatible with thrombosis should lead to discus-
sion with a vascular specialist and imaging studies to exclude 
thrombosis or occlusion should be considered.
bleeding
Patients with giant CAA on warfarin and antiplatelet agents are at 
risk of external or internal bleeding, spontaneously or following 
trauma. Internal bleeding may present with swelling over limbs 
or joints, GI bleeding or haemorrhagic stroke. New symptoms or 
lesions should undergo imaging by ultrasound or CT, and INR 
should be checked. Any CNS symptoms with or without a history 
of trauma such as persistent headache, impaired consciousness 
or neurological signs requires imaging to exclude haemorrhagic 
or thrombotic stroke.
suMMAry
Patients with CAA as a result of KD in childhood are at 
lifelong risk of cardiac complications and require lifetime 
follow- up at specialist regional KD clinics. Those with estab-
lished CAA have a continuing increased risk at all ages; in 
Japan, it has been reported that major adverse cardiovascular 
events occur in 64% of patients within 30 years of diagno-
sis.26The management of suspected myocardial ischaemic 
events in these patients differs from that of adults, who 
have acute coronary syndromes due to atherosclerotic heart 
disease. Each patient at risk requires a PSP to ensure that 
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box 2 Key elements for management of previous Kawasaki disease (Kd) in children and adults
 ► Those who have coronary aneurysms following acute KD, whether persisting or remodelled, are at lifelong risk of coronary thrombosis, 
coronary stenoses and acute coronary syndromes.
 ► An individual’s lifetime risk is related to the severity of residual cardiac pathology (particularly coronary aneurysms) after the initial 
illness.
 ► Every child or adult who has had coronary artery aneurysms (CAA) following KD, whether persisting or remodelled, requires lifelong 
uninterrupted follow- up by a cardiology team within a specialist KD clinic with services agreed by the relevant Congenital Cardiac 
Network and adult interventional cardiology service.
 ► A child with a past history of KD aneurysms, who presents with any symptoms or signs which could be due to aneurysm thrombosis or 
acute coronary syndrome, should be managed using a pathway of care predefined by the local specialist children’s congenital cardiac 
network in accordance with this guidance.
 ► An adult with a past history of KD and CAA, who presents with any symptoms or signs which could be due to aneurysm thrombosis 
or acute coronary syndrome, should be taken directly to a Heart Attack Centre (HAC). Those who present to a local hospital should be 
transferred urgently to a HAC to rule out CAA thrombosis, progressive coronary stenoses or acute coronary syndrome. Delay is likely to 
have an adverse effect on outcome.
 ► Every child or adult followed- up for CAA should have a person- specific protocol (PSP) written, detailing the pathway of care to be 
followed if a suspected acute coronary syndrome should occur.
 ► Aneurysm thrombosis and acute coronary syndromes in patients with previous KD may present with atypical symptoms and initial 
absence of typical changes on the ECG or changes in cardiac enzymes. All patients with chest pain or suspected acute coronary 
syndrome should be imaged urgently to rule out thrombus.
 ► Emergency access to interventional cardiology services will be required to manage suspected acute coronary syndromes in children 
and should be part of the care pathway defined. The congenital cardiac centre and the HAC should ideally be colocated, but where not, 
arrangements for emergency access should be clear, agreed in advance of any need and documented in a PSP.
 ► Congenital Cardiac Networks should take the lead on disseminating learning and best practice in line with this guidance, to all those 
who may be involved in the care of patients who have had KD. Where these do not exist, they should be established with adult and 
paediatric cardiology input and ensure access to specialist cardiac imaging, interventional cardiology and cardiac surgery.
 ► Centralising the follow- up of affected patients will help concentrate and build expertise, enable the development of care pathways for 
the emergency management of acute complications and facilitate research.
 ► Transition of care from a paediatric to adult service should be planned in advance and be well- coordinated.
they reach an appropriately equipped centre with specialist 
expertise and that they do so without delay (Box 2).
Person-specific protocol
See online supplementary file 2.
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